
Onychomycosis (dermatophytosis of the nail) is a chronic fungal infection affecting toenails or fingernails that can involve the nail matrix, nail bed, or nail plate. Although not life-threatening, it causes significant physical discomfort and considerable psychological distress due to altered nail appearance.
Clinical Concept: Particularly in patients with comorbid conditions such as diabetes mellitus, onychomycosis can lead to serious secondary complications including cellulitis, osteomyelitis, and tissue necrosis.
Patients typically present after months of unsuccessful home or over-the-counter remedies. Infected nails are dull, thickened, lusterless, and have a pithy consistency, with parts of the nail often breaking off.
Differential Diagnosis: Conditions mimicking onychomycosis include contact dermatitis, nail psoriasis, traumatic onycholysis, and lichen planus.
Because non-fungal conditions can mimic onychomycosis, diagnostic confirmation is essential:
Oral antifungals—specifically itraconazole (Sporanox®), terbinafine (Lamisil®), and fluconazole (Diflucan®)—are the most effective treatments. Older agents like griseofulvin require months of treatment and carry a high relapse rate.
Pulse Dosing Protocol: Itraconazole 400 mg daily for the first week of the month (given for 2 months for fingernails or 3 months for toenails) alternates drug use with abstinent periods. The medication accumulates in the nail matrix for months post-therapy, yielding high efficacy at lower cost and significantly reduced hepatotoxicity.